Match Document Document Title
8986711 Vaccine to protect animals against leishmania  
The present invention is generally related to the prevention of leishmaniasis in animals, particularly infection caused by Leishmania sp., based on the use of Leishmania infantum P36 protein or an...
8986704 Mutant fragments of OspA and methods and uses relating thereto  
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use...
8986700 Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes  
The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and...
8986706 Newcastle disease virus vectored herpesvirus vaccines  
The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus...
8986708 Combinations of gene deletions for live attenuated Shigella vaccine strains  
Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2...
8980300 Plasticizers for coating compositions  
A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and/or a bioactive...
8980324 Silicon dioxide nanoparticles and the use thereof for vaccination  
The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the...
8980287 Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination  
Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein,...
8980289 Intestine immunomodulator  
The purpose of the present invention is to provide a better intestine immunomodulator. The intestine immunomodulator of the present invention comprises bacterial cells or a bacterial component of...
8980283 C. perfringens alpha toxoid vaccine  
The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any...
8974793 Methods and systems for inducing immunologic tolerance to non-self antigens  
Described herein are methods and systems that can be used to induce immunologic tolerance to non-self antigens. The methods and systems comprise introducing a tolerogen comprising at least one...
8974800 Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines  
The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M....
8974798 Anti-bacterial vaccine compositions with a mutated yleA gene  
Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision...
8968749 Vaccine composition and immunization method  
The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus...
8968743 Method and compositions for cutaneous immunisation  
The invention concerns the development of a system to deliver vaccines via cutaneous route. The invention more particularly concerns the use of a device comprising a condensation compartment for...
8968745 Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same  
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid...
8968716 In situ-forming hydrogel for tissue adhesives and biomedical use thereof  
Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over...
8968719 Live, oral vaccine for protection against Shigella dysenteriae serotype 1  
The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected...
8968748 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis  
The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis...
8968744 Aqueous composition comprising a biological antigen and an acrylic acid polymer  
The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity...
8961995 Methods and compositions for alphavirus replicons  
The present invention provides alphavirus replicons and methods of their use in producing heterologous protein.
8961984 Surface-coated structures and methods  
The present invention relates to a method for covalently attaching a compound to a stainless steel, tin, iron, or titanium substrate, by contacting exposed surface(s) of the substrate with a...
8961977 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies  
The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or...
8961982 Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer  
Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides...
8961983 Mucosal vaccine using cationic nanogel  
A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of...
8956619 Soluble CD80 as a therapeutic to reverse immune supression in cancer patients  
The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune...
8956812 Process for the preparation and purification of recombinant proteins  
A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The...
8956617 Vaccination by transcutaneous targeting  
The present invention relates to a method of vaccination via hair follicles that makes it possible to target vaccine components to the antigen-presenting cells in order to induce a protective and...
8956618 Vaccine vectors and methods of enhancing immune responses  
Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also...
8956620 Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine  
Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions...
8951531 Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides  
This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against...
8951529 Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases  
Methods for enhancing the suppressive function of myeloid derived suppressor cells (MDSCs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the...
8951538 Exopolysaccharide of Shigella sonnei bacteria, method for producing same, vaccine and phamaceutical composition containing same  
For the first time, an O-specific polysaccharide antigen that is a Shigella sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic...
8951572 Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts  
A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human...
8951536 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase  
The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof...
8951532 A25 bacteriophage lysin  
The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life...
8946175 Stabilized immunomodulatory oligonucleotides  
The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5′- or 3′-end. These oligonucleotides have either reduced or...
8945590 Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)  
This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for...
8945589 Immunogenic compositions for Streptococcus agalactiae  
This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a...
8945591 Methods and compositions involving immunostimulatory oligodeoxynucleotides  
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate,...
8945585 Multi-Target recombination gene and the application of its protein to prevent and cure Helicobacter pylori  
The present invention discloses a multi-target recombination gene and the application of its protein to prevent and cure Helicobacter pylori. It includes a multi-target fusion polypeptide having...
8945587 Synthetic lipid biology for combinatorial engineering of endotoxin  
The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different...
8945569 Jagged-binding agents and uses thereof  
Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are...
8940517 Methods for isolating and quantifying antigen from vaccines  
The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure...
8940307 Lectin compositions and methods for modulating an immune response to an antigen  
The present invention also relates to a method of reducing metastases in a subject comprising administering to the subject a composition comprising a multifunctional molecule comprising a first...
8937218 Transformed soybean plant which accumulates vaccine, and use thereof  
A transformed soybean plant having a gene encoding a modified seed storage protein introduced therein, obtained by inserting a gene encoding an Alzheimer's disease vaccine to a variable region(s)...
8936786 Methods and compositions for oral administration of protein and peptide therapeutic agents  
The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles...
8937157 Therapeutic nuclease compositions and methods  
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
8932594 Adjuvants and methods of use  
Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed....
8932595 Nicotine immunonanotherapeutics  
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in...